Sarah C Conner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2840350/publications.pdf

Version: 2024-02-01

1163065 996954 15 457 8 15 citations h-index g-index papers 16 16 16 878 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials. Journal of Clinical Oncology, 2016, 34, 1813-1819.	1.6	171
2	Circulating cortisol and cognitive and structural brain measures. Neurology, 2018, 91, e1961-e1970.	1.1	90
3	Adjusted restricted mean survival times in observational studies. Statistics in Medicine, 2019, 38, 3832-3860.	1.6	39
4	Circulating IGFBPâ€2: a novel biomarker for incident dementia. Annals of Clinical and Translational Neurology, 2019, 6, 1659-1670.	3.7	34
5	Growth Differentiation Factor 15 and NTâ€proBNP as Bloodâ€Based Markers of Vascular Brain Injury and Dementia. Journal of the American Heart Association, 2020, 9, e014659.	3.7	32
6	Midâ€life and lateâ€life vascular risk factor burden and neuropathology in old age. Annals of Clinical and Translational Neurology, 2019, 6, 2403-2412.	3.7	18
7	Is employment status in adults over 25Âyears old associated with nonmedical prescription opioid and stimulant use?. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 291-298.	3.1	16
8	Circulating Vascular Growth Factors and Magnetic Resonance Imaging Markers of Small Vessel Disease and Atrophy in Middle-Aged Adults. Stroke, 2018, 49, 2227-2229.	2.0	12
9	Refining the Association Between Body Mass Index and Atrial Fibrillation: Gâ€Formula and Restricted Mean Survival Times. Journal of the American Heart Association, 2019, 8, e013011.	3.7	12
10	Estimation and modeling of the restricted mean time lost in the presence of competing risks. Statistics in Medicine, 2021, 40, 2177-2196.	1.6	9
11	Methionine Sulfoxide Reductase-B3 Risk Allele Implicated in Alzheimer's Disease Associates with Increased Odds for Brain Infarcts. Journal of Alzheimer's Disease, 2019, 68, 357-365.	2.6	7
12	Insulin-Like Growth Factor, Inflammation, and MRI Markers of Alzheimer's Disease in Predominantly Middle-Aged Adults. Journal of Alzheimer's Disease, 2022, 88, 311-322.	2.6	6
13	Survivorship Bias in Analyses of Immune Checkpoint Inhibitor Trials. JAMA Oncology, 2019, 5, 1226.	7.1	5
14	A comparison of statistical methods to predict the residual lifetime risk. European Journal of Epidemiology, 2022, 37, 173.	5.7	4
15	Reply to K.H. Eng et al. Journal of Clinical Oncology, 2017, 35, 466-467.	1.6	2